**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 57826

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Association between restrictive pulmonary disease and type 2 diabetes in Koreans: A cross-sectional study**

Lee DY *et al*. Restrictive pulmonary disease and T2D

Do Y Lee, Seung M Nam

**Do Y Lee, Seung M Nam,** Department of Physical Therapy, Daegu University, Gyeongsan-si 38453, South Korea

**Author contributions:** Lee DY performed the experiments, interpreted the results, and wrote the manuscript; Nam SM interpreted the results, wrote and revised the manuscript, and supervised the study.

**Corresponding author: Seung M Nam, PhD, Adjunct Professor,** Department of Physical Therapy, Daegu University, 201, Daegudae-ro Gyeongsan-si 38453, South Korea. 20849606@hanmail.net

**Received:** June 25, 2020

**Revised:** August 11, 2020

**Accepted:** August 31, 2020

**Published online:**

**Abstract**

BACKGROUND

Diabetes is a progressive disease that increases glucose levels in the blood. While studies have shown that patients with pulmonary disease (both obstructive and restrictive pulmonary disease) have a higher prevalence of type 2 diabetes mellitus (T2DM), there have been more studies on restrictive patterns than chronic obstructive pulmonary disease.

AIM

To assess whether restrictive and obstructive pulmonary diseases are associated with T2DM in Koreans.

METHODS

For our analysis, we used data from the Korea National Health and Nutrition Examination Survey. A total of 2830 subjects were included in this study. Spirometry results were categorized into three patterns: normal, restrictive pulmonary disease (RPD), and obstructive pulmonary disease (OPD).

RESULTS

The factors used as diabetic indicators (*i.e.* homeostatic model assessment of insulin resistance, homeostatic model assessment of beta-cell function, glycated hemoglobin, and fasting insulin) were among the highest in RPD but not in OPD. Based on multivariate logistic regression analysis, subjects with RPD were found with an increased odds ratio (OR: 1.907, 95% confidence interval (CI): 1.110-3.277) for T2DM compared with subjects with normal pulmonary function, whereas in patients with OPD, the OR had not increased. Model 4, which adjusted for the variables that could affect diabetes and pulmonary disease, showed a significant increase in the T2DM OR to RPD (OR: 2.025, 95%CI: 1.264-3.244). On the other hand, no statistically significant difference was shown in OPD (OR: 0.982, 95%CI: 0.634-1.519).

CONCLUSION

RPD, not OPD, is highly associated with T2DM regardless of the risk factors of various T2DMs that can be confounds.

**Key words:** Restrictive pulmonary disease; Obstructive pulmonary disease; Type 2 diabetes mellitus; Insulin resistance; Glycated hemoglobin; Koreans

Lee DY, Nam SM. Association between restrictive pulmonary disease and type 2 diabetes in Koreans: A cross-sectional study. *World J Diabetes* 2020; In press

**Core tip:** This study was performed to assess whether restrictive and obstructive patterns of pulmonary disease and type 2 diabetes mellitus (T2DM) are associated with each other in Koreans. For our analysis, we used data from the Korea National Health and Nutrition Examination Survey. A total of 2830 subjects were included in this study. Spirometry results were categorized into three patterns: normal, restrictive, and obstructive pulmonary disease. Restrictive pulmonary disease, not obstructive disease, is highly relevant to T2DM regardless of other risk factors of various T2DMs that can be confounds.

**INTRODUCTION**

Diabetes is a progressive disease that increases glucose levels in the blood and has several pathogeneses, including insulin resistance in the liver and dysfunction of pancreas beta cells[1,2]. Type 2 diabetes mellitus(T2DM) is a complex disease associated with increased risk of multiple complications, such as peripheral circulation disease, and cardiovascular diseases such as stroke and coronary artery disease requiring intervention for treatment and prevention[3]. The cause of these cardiovascular diseases has been reported to be the increase in inflammation levels due to hyperglycemia and the weakening of cardiopulmonary functions[4]. Also, an increase of 1% of glycated hemoglobin (HbA1c), a blood sugar control factor, is known to increase the risk of cardiovascular disease by 28%[5]. Moreover, in a recent study, the risk of pulmonary dysfunction was higher in patients with impaired fasting glucose levels[6]. In addition, subjects with T2DM decreased forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) regardless of race[7-9].

There are restrictive and obstructive pulmonary diseases in impaired pulmonary function[10]. Restrictive pulmonary disease (RPD) is reduced in both FVC and FEV1, resulting from a defect in thoracic compatibility[11]. On the other hand, obstructive pulmonary disease (OPD) is known to be caused by a significant reduction in FEV1, mainly due to airway blockages associated with smoking[12]. According to previous studies, impaired pulmonary function causes insulin resistance[13-15]. In addition, an increase in the inflammatory response derived from obesity causes insulin resistance and increases the risk of cardiovascular disease associated with obesity[16]. It was shown in previous studies that the prevalence rate of T2DM in chronic OPD patients is high[17,18], whereas it is more related to RPD than chronic OPD[19,20].

As such, the association between T2DM and impaired pulmonary function is not consistently explained. In addition, it is not clear whether this association is mediated by insulin resistance or by other factors. Therefore, based on the cross-sectional data from a large number of Korean subjects, this study examined the association between RPD and OPD with insulin resistance and T2DM.

**MATERIALS AND METHODS**

***Data source and sampling***

This study obtained data from the Korea National Health and Nutrition Examination Survey (KNHANES), 2015, a cross-sectional and nationally representative survey conducted by the Korean Centers for Diseases Control and Prevention. The subjects were designated as those who responded to both the examination and the health survey among adults aged 40 or older who were subjected to the pulmonary function measurement. Among 7380 subjects that participated in KNHANES, 3008 subjects under 40 years of age, 1401 subjects who did not measure pulmonary function, 105 subjects who did not measure T2DM components, and 105 subjects who did not do the health survey were excluded. A total of 2830 participants were eligible for this study (Figure 1).

***Measurements of variables***

**Covariates:** Body mass index (BMI) was calculated by dividing weight (kg) by height (m). Waist circumference (WC) was measured at the midpoint between the bottom of the rib cage and the top of the lateral border of the iliac crest with full expiration. Blood samples were collected from subjects in the morning after overnight fasting and analyzed at a national central laboratory. Blood pressure was measured using a mercury sphygmomanometer in a seated position after a 10-min rest period. Two measurements were made for all subjects at 5-min intervals. An average of two measurements was used for the data analyses. Cigarette smoking condition was categorized as never smokers, ex-smokers, and current smokers, and drinking condition was dichotomized as current users and non-users. Physical examinations included HbA1c, C-reactive protein (hs-CRP), fasting insulin, fasting glucose, waist circumference, diastolic and systolic blood pressure, total cholesterol, low density lipoprotein, high density lipoprotein-cholesterol, and triglyceride measurement variables.

***Measurement of pulmonary function***

Pulmonary function was measured using a spirometer (model 2130; SensorMedics, Yorba Linda, CA, Untied States). Participants were classified according to respiratory patterns into a normal group (FEV 1/FVC ≥ 0.70, FVC ≥ 80% predicted), an OPD group (FEV 1/FVC < 0.70), and a RPD group (FVC < 80% predicted, FEV 1 / FVC ≥ 0.70)[21].

***T2DM and insulin resistance***

Homeostasis model assessment (HOMA) was used to calculate insulin resistance HOMA-IR and beta-cell function HOMA-beta indices using the formula: HOMA-IR = [fasting glucose (mg/dL) × fasting insulin (μU/mL)]/405 (> 2.5 indicating a high index of IR)[22] and HOMA-beta = [fasting insulin (lU/mL) 360]/[fasting glucose (mg/dL)-63][23].

Diabetes mellitus was defined by fasting glucose levels > 126 mg/dL in the health examination. Type 2 diabetes was distinguished from type 1 diabetes based on age at onset and treatment with insulin. Impaired fasting glucose (IFG) was defined as fasting glucose levels ≥ 100 mg/dL and < 125 mg/dL. Also, even if data such as fasting glucose and fasting insulin were normal, those who answered "yes" in the survey on whether they take diabetes drugs were classified as diabetic patients.

***Statistical analysis***

Since this study uses a complex sampling design, the weight given by the KNHANES has been applied. General characteristics were compared according to the pulmonary function and the prevalence of T2DM through the Chi-square test. A logistic regression analysis was used to analyze the association between pulmonary disease and T2DM, and *P* values < 0.05 were considered statistically significant. Data analysis uses the Statistic Package for Social Science 22.0 window version (Armonk, NY, United States).

**RESULTS**

In this study, the prevalence of RPD was 8.86% and OPD 14.20%. Significant differences by pulmonary disease were found in all variables except diastolic blood pressure and drinking status. Compared with those in the normal group, RPD and OPD subjects were of older age, with greater waist circumference, higher systolic blood pressure, and higher triglyceride. Also, smokers and men were higher in OPD than in normal and RPD. In terms of T2DM prevalence due to pulmonary disease, RPD accounted for 21.1%, the highest. In addition, the factors used as diabetic indicators, HOMA-IR, HOMA-beta, HbA1c, and fasting insulin, were all among the highest in the RPD, not in the OPD, compared to subjects with normal pulmonary function. hs-CRP, which indicates inflammation levels, was also the highest in the RPD (7.80 *vs* 9.84 *vs* 8.07) (Table 1).

Comparing pulmonary disease with fasting glucose levels, subjects with abnormal glucose levels (T2DM or IFG) had a higher prevalence rate of RPD and OPD compared to normal levels. In normal and IFG, the prevalence of RPD was significantly lower than that of OPD, but RPD was higher in T2DM (RPD/OPD: 6.2/11.5 *vs* 8.4/13.3 *vs* 18.1/15.9). In addition, HOMA-IR, HbA1c, and fasting insulin were higher with abnormal glucose levels, while HOMA-beta was significantly lower. The inflammatory factor Hs-CRP also higher in IFG and T2DM compared to normal.

To find out the association between pulmonary disease in subjects who do not have diabetes but are more likely to develop T2DM, multiple regression analyses were performed by dividing levels of normal, IFG, and T2DM groups (Table 2). Model 1, which adjusted for age and sex, showed that the probability of RPD was 1.453 times (95% confidence interval (CI): 1.059-1.995) for IFG and 3.621 times (95%CI: 2.316-5.663) for T2DM. However, Model 4, which adjusted for all variables that could be influential, showed 1.907 times (CI: 1.110-3.277) for T2DM. In contrast, the analysis of the association between OPD and IFG showed no significant association in any model (Table 3). Model 4, which adjusted for the variables that could affect diabetes and pulmonary disease, showed a significant increase in the T2DM odds ratio (OR) to the RPD (OR: 2.025, 95%CI: 1.264–3.244). On the other hand, no statistically significant difference was shown in OPD (OR: 0.982, 95%CI: 0.634–1.519) (Table 4).

**DISCUSSION**

This cross-sectional study is intended to identify the association of abnormal glucose in pulmonary disease. In particular, RPD was highly associated with increased ORs of T2DM regardless of major potential confounds, such as age and obesity factors. Thus, the main findings of this study are that T2DM is highly related to RPD but not OPD.

Pulmonary disease is associated with T2DM risk factors such as smoking, HbA1c, insulin resistance, hyperglycemia, and abdominal obesity, and these associations are particularly prominent in RPD[24,25]. The results of this study also showed significantly higher indicators of HbA1c, HOMA-IR, fasting glucose, and waist circumference in RPD compared to normal and OPD.

Although smoking is known to be a major cause of reduced pulmonary function[26], the results of this study show that it does not affect RPD. It has been confirmed to influence OPD. Other prior studies have shown that the association between RPD and T2DM prevalence rates is not significantly changed by smoking conditions, indicating that smoking has little influence.

HbA1c, measured for diagnosis of T2DM and monitoring glucose control, is a risk factor for cardiovascular disease[27]. In this study, the HbA1c level of RPD was the highest compared to normal and OPD (5.71 *vs* 6.14 *vs* 5.93). These results are consistent with the results of a prior study that showed a link between HbA1c and reduced pulmonary function in diabetics[28]. Moreover, the high level of HbA1c in healthy individuals means poor lung capacity, especially RPD[25].

Although pathological mechanisms for explaining the association between reduced pulmonary function and insulin resistance and T2DM have not been identified, there may be several common underlying causes. First, insulin resistance and hyperglycemia, the main risk factors for T2DM, caused decreased pulmonary function[29]. One study reported that insulin receptors exist in the lung pleura[30], and this insulin can change the physiology, which can promote deterioration of the respiratory muscle due to changes in glucose absorption in the thoracic muscle[31]. The results of this study indicate that HOMA-IR and fasting glucose figures are significantly higher in the RPD compared to normal and OPD, consistent with this hypothesis.

Second, the accumulation of fat in the abdominal cavity reduces lung volume and decreases the motion of the diaphragm, so pulmonary function is likely to be reduced[32,33]. The results of this study show that WC and BMI are significantly higher in RPD and OPD than in normal groups, supporting this hypothesis. However, there is no statistically significant difference between the WC and BMI of RPD and OPD. In other words, abdominal obesity may be the basis for explaining the association between decreased pulmonary function and T2DM, but it does not seem to explain fully the relationship between RPD and T2DM.

Third, systemic inflammatory responses with insulin resistance lead to reduced pulmonary function and the development of diabetes[34]. Visceral fat, one of the risk factors for diabetes, affects the concentration of cytokines in the blood such as interleukin-6, adiponectin, leptin, and tumor necrosis factor-α, causing systemic inflammatory reactions and chronic low-grade inflammation reduced pulmonary function[35,36]. In this study, the hs-CRP, an indicator of systemic inflammatory reactions, was the highest in RPD, and the prior study is consistent with the findings that the increase in hs-CRP is highly related to pulmonary disease[37-39].

To summarize, there was a significant association between RPD and T2DM, whereas IFG was weak or not present. This suggests that T2DM is not a result of RPD, rather the cause of T2DM. Thus, it can be seen that risk factors, such as HOMA-IR, HbA1c, hyperglycemia, abdominal fat, and inflammatory index hs-CRP, are not sufficient in IFG to cause RPD compared to T2DM. Therefore, it would be worthwhile to examine the pulmonary function of IFG patients in future longitudinal studies according to the pattern of their T2DM progression.

Despite several meaningful findings of this study, there are several limitations. First, we could not use a specialized method to measure insulin resistance. However, it is reported that there is a high correlation between HOMA-IR and whole-body glucose absorption, measured using the euglycemic hyperinsulinemic clamp method. Second, because KNHANES's individuals who participated in this survey have relatively mild levels of comorbidities, a small number of severe-stage diabetics or pulmonary disease patients may affect the outcome analysis. In addition, the proportion of IFG or T2DM may have been somewhat high only for those aged 40 or older who conducted the pulmonary function tests. However, the strength of this data is that there is a high response rate, and it is thought that potential confounds will not have a significant impact on the results because it has been obtained from the representative information of a Korean population. Third, this study could not determine the temporal relationship because it was a cross-sectional design. This made it impossible to pinpoint the sequence of fundamental causes between pulmonary disease and T2DM. Therefore, it would be worthwhile to identify the mechanism between the two through future longitudinal studies.

**CONCLUSION**

This study was conducted to determine the association between pulmonary disease and T2DM. It was found that restrictive pulmonary function, not obstructive, is highly relevant to T2DM regardless of the various risk factors of T2DM that can be confounds.

**ARTICLE HIGHLIGHTS**

***Research background***

Previously, the association between type 2 diabetes mellitus (T2DM) and pulmonary disease was confirmed. Some studies found that T2DM is related to obstructive pulmonary disease (OPD), and others have shown that it is related to restrictive pulmonary disease (RPD).

***Research motivation***

T2DM and RPD are highly connected with T2DM, but research on causality between them is insufficient. Therefore, it is important to study this.

***Research objectives***

To find out the association between T2DM and pulmonary disease and to reveal its causal relationship.

***Research methods***

Korea National Health and Nutrition Examination Survey (KNHANES) is a survey research program conducted by the Korean Centers for Diseases Control and Prevention to assess the health and nutritional status of adults and children in Korea and to track changes over time. The survey combines interviews, physical examinations, and laboratory tests. KNHANES interview includes demographic, socioeconomic, dietary, and health-related questions. The examination component consists of medical, dental, and physiological measurements as well as laboratory tests administered by medical personnel, and all data are made anonymous and can be officially downloaded from the website. The KNHANES data are the official national disclosure data conducted annually. The data in this study are complex sampling design, using logistic regression analysis that is most appropriate to view the association between the variables recommended by the Korean Centers for Diseases Control.

***Research results***

Compared to OPD, the ratio of T2DM and its risk factors in restrictive RPD was very high. In addition, the analysis of pulmonary disease by fasting glucose level showed no significant difference in impaired fasting glucose group, and in T2DM, the probability of RPD occurring was 1.907 times higher than that of OPD. Also, the results of this study have significant association between RPD and T2DM, whereas impaired fasting glucose was weak or not present.

***Research conclusions***

RPD is highly relevant to T2DM regardless of risk factors. To summarize, this study suggests that RPD is not a cause of T2DM but rather a consequence of T2DM.

***Research perspectives***

In the future, a longitudinal study should identify changes in pulmonary function of impaired fasting glucose as it progresses.

**REFERENCES**

1 **Sonne DP**, Hemmingsen B. Comment on American Diabetes Association. *Standards of Medical Care in Diabetes-2017*. Diabetes Care 2017;40(Suppl. 1):S1-S135. *Diabetes Care* 2017; **40**: e92-e93 [PMID: 28637892 DOI: 10.2337/dc17-0299]

2 **Hawkins D**, Bradberry JC, Cziraky MJ, Talbert RL, Bartels DW, Cerveny JD; National Pharmacy Cardiovascular Council. National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles for pharmacists. *Pharmacotherapy* 2002; **22**: 436-444 [PMID: 11939679 DOI: 10.1592/phco.22.7.436.33667]

3 **Einarson TR**, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. *Cardiovasc Diabetol* 2018; **17**: 83 [PMID: 29884191 DOI: 10.1186/s12933-018-0728-6]

4 **Walther C**, Möbius-Winkler S, Linke A, Bruegel M, Thiery J, Schuler G, Halbrecht R. Regular exercise training compared with percutaneous intervention leads to a reduction of inflammatory markers and cardiovascular events in patients with coronary artery disease. *Eur J Cardiovasc Prev Rehabil* 2008; **15**: 107-112 [PMID: 18277195 DOI: 10.1097/HJR.0b013e3282f29aa6]

5 **Lind M**, Tuomilehto J, Uusitupa M, Nerman O, Eriksson J, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Peltonen M, Pivodic A, Lindström J. The association between HbA1c, fasting glucose, 1-hour glucose and 2-hour glucose during an oral glucose tolerance test and cardiovascular disease in individuals with elevated risk for diabetes. *PLoS One* 2014; **9**: e109506 [PMID: 25285769 DOI: 10.1371/journal.pone.0109506]

6 **Kim HK**, Kim CH, Jung YJ, Bae SJ, Choe J, Park JY, Lee KU. Association of restrictive ventilatory dysfunction with insulin resistance and type 2 diabetes in koreans. *Exp Clin Endocrinol Diabetes* 2011; **119**: 47-52 [PMID: 21246464 DOI: 10.1055/s-0030-1268467]

7 **Klein OL**, Aviles-Santa L, Cai J, Collard HR, Kanaya AM, Kaplan RC, Kinney GL, Mendes E, Smith L, Talavera G, Wu D, Daviglus M. Hispanics/Latinos With Type 2 Diabetes Have Functional and Symptomatic Pulmonary Impairment Mirroring Kidney Microangiopathy: Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). *Diabetes Care* 2016; **39**: 2051-2057 [PMID: 27612502 DOI: 10.2337/dc16-1170]

8 **Lecube A**, Simó R, Pallayova M, Punjabi NM, López-Cano C, Turino C, Hernández C, Barbé F. Pulmonary Function and Sleep Breathing: Two New Targets for Type 2 Diabetes Care. *Endocr Rev* 2017; **38**: 550-573 [PMID: 28938479 DOI: 10.1210/er.2017-00173]

9 **Lee YJ**, Kim NK, Yang JY, Noh JH, Lee SS, Ko KS, Rhee BD, Kim DJ. Low pulmonary function in individuals with impaired fasting glucose: the 2007-2009 Korea national health and nutrition examination survey. *PLoS One* 2013; **8**: e76244 [PMID: 24086719 DOI: 10.1371/journal.pone.0076244]

10 **Schroeder EB**, Welch VL, Couper D, Nieto FJ, Liao D, Rosamond WD, Heiss G. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. *Am J Epidemiol* 2003; **158**: 1171-1181 [PMID: 14652302 DOI: 10.1093/aje/kwg276]

11 **Reeves-Hoche MK**, Meck R, Zwillich CW. Nasal CPAP: an objective evaluation of patient compliance. *Am J Respir Crit Care Med* 1994; **149**: 149-154 [PMID: 8111574 DOI: 10.1164/ajrccm.149.1.8111574]

12 **Tkacova R**. Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives. *Mediators Inflamm* 2010; **2010**: 585989 [PMID: 20414465 DOI: 10.1155/2010/585989]

13 **Engström G**, Janzon L. Risk of developing diabetes is inversely related to lung function: a population-based cohort study. *Diabet Med* 2002; **19**: 167-170 [PMID: 11874435 DOI: 10.1046/j.1464-5491.2002.00652.x]

14 **Engström G**, Hedblad B, Nilsson P, Wollmer P, Berglund G, Janzon L. Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort study. *J Intern Med* 2003; **253**: 574-581 [PMID: 12702035 DOI: 10.1046/j.1365-2796.2003.01138.x]

15 **Litonjua AA**, Lazarus R, Sparrow D, Demolles D, Weiss ST. Lung function in type 2 diabetes: the Normative Aging Study. *Respir Med* 2005; **99**: 1583-1590 [PMID: 16291079 DOI: 10.1016/j.rmed.2005.03.023]

16 **Fantuzzi G**. Adipose tissue, adipokines, and inflammation. *J Allergy Clin Immunol* 2005; **115**: 911-9; quiz 920 [PMID: 15867843 DOI: 10.1016/j.jaci.2005.02.023]

17 **Vijayan VK**. Chronic obstructive pulmonary disease. *Indian J Med Res* 2013; **137**: 251-269 [PMID: 23563369]

18 **Stojkovikj J**, Zafirova-Ivanovska B, Kaeva B, Anastasova S, Angelovska I, Jovanovski S, Stojkovikj D. The Prevalence of Diabetes Mellitus in COPD Patients with Severe and Very Severe Stage of the Disease. *Open Access Maced J Med Sci* 2016; **4**: 253-258 [PMID: 27335596 DOI: 10.3889/oamjms.2016.060]

19 **Lange P**, Parner J, Schnohr P, Jensen G. Copenhagen City Heart Study: longitudinal analysis of ventilatory capacity in diabetic and nondiabetic adults. *Eur Respir J* 2002; **20**: 1406-1412 [PMID: 12503696 DOI: 10.1183/09031936.02.00050502]

20 **Kopf S**, Groener JB, Kender Z, Fleming T, Brune M, Riedinger C, Volk N, Herpel E, Pesta D, Szendrödi J, Wielpütz MO, Kauczor HU, Katus HA, Kreuter M, Nawroth PP. Breathlessness and Restrictive Lung Disease: An Important Diabetes-Related Feature in Patients with Type 2 Diabetes. *Respiration* 2018; **96**: 29-40 [PMID: 29874679 DOI: 10.1159/000488909]

21 **Knudson RJ**, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. *Am Rev Respir Dis* 1983; **127**: 725-734 [PMID: 6859656 DOI: 10.1164/arrd.1983.127.6.725]

22 **Taura N**, Ichikawa T, Hamasaki K, Nakao K, Nishimura D, Goto T, Fukuta M, Kawashimo H, Fujimoto M, Kusumoto K, Motoyoshi Y, Shibata H, Abiru N, Yamasaki H, Eguchi K. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. *Am J Gastroenterol* 2006; **101**: 2752-2759 [PMID: 17026566 DOI: 10.1111/j.1572-0241.2006.00835.x]

23 **Dai CY**, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Yu ML. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. *J Hepatol* 2009; **50**: 712-718 [PMID: 19231011 DOI: 10.1016/j.jhep.2008.12.017]

24 **Lim SY**, Rhee EJ, Sung KC. Metabolic syndrome, insulin resistance and systemic inflammation as risk factors for reduced lung function in Korean nonsmoking males. *J Korean Med Sci* 2010; **25**: 1480-1486 [PMID: 20890430 DOI: 10.3346/jkms.2010.25.10.1480]

25 **Oh IH**, Park JH, Lee CH, Park JS. The association of normal range glycated hemoglobin with restrictive lung pattern in the general population. *PLoS One* 2015; **10**: e0117725 [PMID: 25658743 DOI: 10.1371/journal.pone.0117725]

26 **Jayes L**, Haslam PL, Gratziou CG, Powell P, Britton J, Vardavas C, Jimenez-Ruiz C, Leonardi-Bee J; Tobacco Control Committee of the European Respiratory Society. SmokeHaz: Systematic Reviews and Meta-analyses of the Effects of Smoking on Respiratory Health. *Chest* 2016; **150**: 164-179 [PMID: 27102185 DOI: 10.1016/j.chest.2016.03.060]

27 **Furuya A**, Suzuki S, Koga M, Oshima M, Amamiya S, Nakao A, Wada K, Okuhara K, Hayano S, Matsuo K, Tanahashi Y, Azuma H. HbA1c can be a useful glycemic control marker for patients with neonatal diabetes mellitus older than 20 wk of age. *Clin Chim Acta* 2014; **436**: 93-96 [PMID: 24854496 DOI: 10.1016/j.cca.2014.05.005]

28 **Ehrlich SF**, Quesenberry CP Jr, Van Den Eeden SK, Shan J, Ferrara A. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. *Diabetes Care* 2010; **33**: 55-60 [PMID: 19808918 DOI: 10.2337/dc09-0880]

29 **Lazarus R**, Sparrow D, Weiss ST. Baseline ventilatory function predicts the development of higher levels of fasting insulin and fasting insulin resistance index: the Normative Aging Study. *Eur Respir J* 1998; **12**: 641-645 [PMID: 9762793 DOI: 10.1183/09031936.98.12030641]

30 **Kouritas VK**, Hatzoglou C, Ioannou M, Gourgoulianis KI, Molyvdas PA. Insulin alters the permeability of sheep pleura. *Exp Clin Endocrinol Diabetes* 2010; **118**: 304-309 [PMID: 19856254 DOI: 10.1055/s-0029-1233452]

31 **Ribeiro MJ**, Sacramento JF, Gonzalez C, Guarino MP, Monteiro EC, Conde SV. Carotid body denervation prevents the development of insulin resistance and hypertension induced by hypercaloric diets. *Diabetes* 2013; **62**: 2905-2916 [PMID: 23530003 DOI: 10.2337/db12-1463]

32 **Canoy D**, Luben R, Welch A, Bingham S, Wareham N, Day N, Khaw KT. Abdominal obesity and respiratory function in men and women in the EPIC-Norfolk Study, United Kingdom. *Am J Epidemiol* 2004; **159**: 1140-1149 [PMID: 15191931 DOI: 10.1093/aje/kwh155]

33 **Salome CM**, King GG, Berend N. Physiology of obesity and effects on lung function. *J Appl Physiol (1985)* 2010; **108**: 206-211 [PMID: 19875713 DOI: 10.1152/japplphysiol.00694.2009]

34 **Mannino DM**, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. *Am J Med* 2003; **114**: 758-762 [PMID: 12829203 DOI: 10.1016/s0002-9343(03)00185-2]

35 **Kern PA**, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. *Am J Physiol Endocrinol Metab* 2001; **280**: E745-E751 [PMID: 11287357 DOI: 10.1152/ajpendo.2001.280.5.E745]

36 **Lazarus R**, Sparrow D, Weiss ST. Impaired ventilatory function and elevated insulin levels in nondiabetic males: the Normative Aging Study. *Eur Respir J* 1998; **12**: 635-640 [PMID: 9762792 DOI: 10.1183/09031936.98.12030635]

37 **Rutter MK**, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. *Circulation* 2004; **110**: 380-385 [PMID: 15262834 DOI: 10.1161/01.CIR.0000136581.59584.0E]

38 **Jung DH**, Shim JY, Ahn HY, Lee HR, Lee JH, Lee YJ. Relationship of body composition and C-reactive protein with pulmonary function. *Respir Med* 2010; **104**: 1197-1203 [PMID: 20299196 DOI: 10.1016/j.rmed.2010.02.014]

39 **Okita K**, Iwahashi H, Kozawa J, Okauchi Y, Funahashi T, Imagawa A, Shimomura I. Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy. *Endocr J* 2013; **60**: 283-290 [PMID: 23149658 DOI: 10.1507/endocrj.ej12-0320]

**Footnotes**

**Institutional review board statement:** The Korea national health and nutrition examination survey (KNHANES, 2015) is a research ethics review that corresponds to research conducted by the government for public welfare in accordance with article 2, paragraph 1 of the bioethics act and article 2, paragraph 1 of the enforcement rule of the same act. Conducted without deliberation by the committee.

**Conflict-of-interest statement:** All the authors have no conflicts of interest related to the manuscript.

**Data sharing statement:** All data have been anonymized and can be officially downloaded from the website. <https://knhanes.cdc.go.kr/knhanes/main.do>

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** June 25, 2020

**First decision:** July 30, 2020

**Article in press:**

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** South Korea

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C, C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Nayak S, Saisho Y, Zhang LL **S-Editor:** Zhang H **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**



**Figure 1** **Subject selection from the Korea National Health and Nutrition Examination Survey 2015.**

**Table 1 Characteristics of individuals with normal, restrictive, and obstructive pulmonary disease**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Normal, *n* = 2177** | **RPD, *n* = 251** | **OPD, *n* = 402** |
| Age (yr)1 | 53.50 ± 0.27a | 57.79 ± 0.81b | 62.40 ± 0.65c |
| Male (%)1 | 45.1a | 50.8a | 78.5b |
| T2DM (%)1 | 7.9a | 21.1b | 12.2c |
| HOMA-IR1 | 2.10 ± 0.07a | 3.13 ± 0.41b | 2.21 ± 0.14a |
| HOMA-beta1 | 78.51 ± 2.50a | 83.13 ± 4.07b | 76.23 ± 3.83c |
| HbA1c (%)1 | 5.71 ± 0.02a | 6.14 ± 0.09b | 5.93 ± 0.06bc |
| Hs-CRP (mg/L)1 | 1.07 ± 0.05a | 1.79 ± 0.19b | 1.48 ± 0.17a |
| Fasting insulin (UIU/mL)1 | 7.80 ± 0.16a | 9.84 ± 0.61b | 8.07 ± 0.43a |
| BMI (kg/m2)1 | 24.08 ± 0.07a | 25.67 ± 0.23b | 24.08 ± 0.16a |
| Fasting glucose (mg/dL)1 | 101.99 ± 0.67a | 116.33 ± 3.64b | 105.85 ± 1.62c |
| Waist circumference (cm)1 | 82.97 ± 0.22a | 87.59 ± 0.60b | 86.29 ± 0.45b |
| SBP (mmHg)1 | 119.46 ± 0.42a | 123.83 ± 1.27b | 124.47 ± 0.85b |
| DBP (mmHg)1 | 77.22 ± 0.26 | 76.53 ± 0.86 | 76.27 ± 0.659 |
| Total cholesterol (mg/dL)1 | 197.35 ± 0.89a | 190.21 ± 2.59b | 191.86 ± 2.43b |
| LDL-cholesterol (mg/dL)1 | 118.97 ± 0.81a | 114.61 ± 2.21a | 116.41 ± 2.37b |
| HDL-cholesterol (mg/dL)1 | 50.73 ± 0.34a | 47.97 ± 0.88b | 46.62 ± 0.68b |
| Triglyceride (mg/dL)1 | 148.73 ± 3.28a | 155.62 ± 11.25b | 157.15 ± 7.17c |
| Smoking status (%) (non-/ex-/current smoker)1 | 57.6/24.2/18.3a | 56.7/25.3/18.0a | 30.8/40.3/28.9b |
| Drinking alcohol status (%) (non-/current drinking) | 25.6/74.4 | 30.5/69.5 | 23.3/76.7 |
| FVC (% predicted)1 | 3.69 ± 0.02a | 2.88 ± 0.04b | 3.83 ± 0.07a |
| FEV1 (L)1 | 2.93 ± 0.02a | 2.29 ± 0.04b | 2.48 ± 0.05c |
| FEV1/FVC1 | 0.80 ± 0.00a | 0.80 ± 0.00a | 0.64 ± 0.00b |
| PEF (L/s)1 | 7.75 ± 0.06a | 6.55 ± 0.12b | 6.67 ± 0.11b |

1*P* < 0.05 by ANOVA or chi-square test. a,b,cThe same letters indicate non-significant difference between groups based on Bonferroni multiple comparison test. Data were presented as means ± SD or *n* (%). T2DM: Type 2 diabetes mellitus; Hs-CRP: Hs-C-reactive protein; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; LDL-cholesterol: Low density lipoprotein-cholesterol; HDL-cholesterol: High density lipoprotein-cholesterol. FVC: Forced vital capacity; FEV1: Forced expiratory volume 1.

**Table 2 Characteristics of individuals with pulmonary function in normal, impaired fasting glucose, and type 2 diabetic subjects**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Normal, *n* = 1608** | **IFG, *n* = 934** | **T2DM, *n* = 288** |
| Age (yr)1 | 53.63 ± 0.31a | 56.23 ± 0.40b | 58.95 ± 0.71c |
| Male (%)1 | 42.9 ± 1.3a | 58.2 ± 1.7b | 62.0 ± 3.5b |
| RPD/OPD (%)1 | 6.2/11.5a | 8.4/13.3b | 18.1/15.9c |
| HOMA-IR1 | 1.45 ± 0.03a | 2.49 ± 0.06b | 5.52 ± 0.58c |
| HOMA-beta1 | 84.75 ± 1.58a | 76.38 ± 1.93b | 48.56 ± 3.96c |
| HbA1c (%)1 | 5.47 ± 0.01a | 5.79 ± 0.02b | 7.61 ± 0.12c |
| Hs-CRP (mg/L)1 | 0.94 ± 0.04a | 1.34 ± 0.09b | 2.04 ± 0.30c |
| Fasting insulin (UIU/mL)1 | 6.42 ± 0.12a | 9.35 ± 0.24b | 13.02 ± 1.05c |
| BMI (kg/m2)1 | 23.63 ± 0.08a | 24.97 ± 0.11b | 25.19 ± 0.22b |
| Fasting glucose (mg/dL)1 | 90.84 ± 0.16a | 107.44 ± 0.26b | 168.79 ± 3.34c |
| Waist circumference (cm)1 | 81.52 ± 0.24a | 86.44 ± 0.31b | 88.32 ± 0.57c |
| SBP (mmHg)1 | 117.92 ± 0.46a | 123.00 ± 0.58b | 126.55 ± 1.14c |
| DBP (mmHg)1 | 76.39 ± 0.32a | 78.18 ± 0.39b | 77.10 ± 0.75a |
| Total cholesterol (mg/dL)1 | 196.00 ± 0.96a | 198.67 ± 1.46a | 186.82 ± 2.73b |
| LDL-cholesterol (mg/dL)1 | 118.77 ± 0.91a | 120.50 ± 1.30a | 107.90 ± 2.26b |
| HDL-cholesterol (mg/dL)1 | 51.71 ± 0.39a | 48.25 ± 0.46b | 45.30 ± 0.72c |
| Triglyceride (mg/dL)1 | 130.65 ± 3.08a | 166.09 ± 5.44b | 216.02 ± 15.20c |
| Smoking status (%) (non-/ex-/current smoker)1 | 59.9/22.1/18.0a | 46.6/32.0/21.4b | 45.6/31.7/22.8b |
| Drinking alcohol status (%)  (non-/current drinking) | 26.4/73.6 | 23.6/76.4 | 28.9/71.1 |
| FVC (% predicted)1 | 3.61 ± 0.26a | 3.72 ± 0.04b | 3.56 ± 0.07a |
| FEV1 (L)1 | 2.81 ± 0.02a | 2.86 ± 0.03ab | 2.72 ± 0.05ac |
| FEV1/FVC1 | 0.78 ± 0.00a | 0.77 ± 0.00b | 0.77 ± 0.01b |
| PEF (L/sec)1 | 7.42 ± 0.06a | 7.73 ± 0.09b | 7.48 ± 0.15ab |

1*P* < 0.05 by ANOVA or chi-square test. a,b,cThe same letters indicate non-significant difference between groups based on Bonferroni multiple comparison test. Data were presented as means ± SD or *n* (%). IFG: Impaired fasting glucose; T2DM: Type 2 diabetes mellitus; Hs-CRP: Hs-C-reactive protein; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; LDL-cholesterol: Low density lipoprotein-cholesterol; HDL-cholesterol: High density lipoprotein-cholesterol; FVC: Forced vital capacity; FEV1: Forced expiratory volume 1.

**Table 3 Odds ratios for pulmonary function according to the fasting glucose level by multivariate logistic regression analysis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Pulmonary disease** | **Fasting glucose odds ratio (95%CI)** | |
| **IFG (100-125)** | **T2DM ( ≥ 126)** |
| Model 1 | RPD | 1.453 (1.059-1.995)a | 3.621 (2.316-5.663) |
|  | OPD | 1.199 (0.888-1.619) | 1.744 (1.164-2.614)a |
| T2DM | RPD | 1.282 (0.939-1.749) | 2.890 (1.810-4.616)b |
|  | OPD | 0.725 (0.518-1.014) | 0.821 (0.525-1.284) |
| Model 3 | RPD | 1.074 (0.781-1.476) | 2.316 (1.438-3.729)b |
|  | OPD | 0.699 (0.498-0.982) | 0.796 (0.501-1.267) |
| Model 4 | RPD | 0.934 (0.638-1.369) | 1.907 (1.110-3.277)a |
|  | OPD | 0.722 (0.512-1.019) | 0.782 (0.484-1.263) |

a*P* < 0.01, b*P* < 0.001. Model 1: Crude; Model 2: Adjusted for age, sex; Model 3: Adjusted for variables in Model 2 + body mass index, waist circumference, smoking status; Model 4: Adjusted for variables in Model 3 + C-reactive protein, homeostasis model assessment-IR. Reference category: Individuals with normal. RPD: Restrictive pulmonary disease; OPD: Obstructive pulmonary disease; IFG: Impaired fasting glucose; T2DM: Type 2 diabetes mellitus.

**Table 4 Odds ratios for type 2 diabetes mellitus according to the pulmonary function by multivariate logistic regression analysis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Pulmonary disease** | **Odds ratio** | **95%CI** |
| Model 1 | RPD | 3.127b | 2.056-4.756 |
|  | OPD | 1.631a | 1.103-2.412 |
| Model 2 | RPD | 2.580b | 1.670-3.988 |
|  | OPD | 1.033 | 0.673-1.584 |
| Model 3 | RPD | 2.257b | 1.465-3.475 |
|  | OPD | 0.984 | 0.633-1.531 |
| Model 4 | RPD | 2.025a | 1.264-3.244 |
|  | OPD | 0.982 | 0.634-1.519 |

a*P* < 0.01, b*P* < 0.001. Model 1: Crude; Model 2: Adjusted for age, sex; Model 3: Adjusted for variables in model 2 + body mass index, waist circumference, smoking status; Model 4: Adjusted for variables in model 3 + C-reactive protein, homeostasis model assessment -IR. Reference category: Individuals with normal. RPD: Restrictive pulmonary disease; OPD: Obstructive pulmonary disease.